Fibrinogen and collagen in plasma will bind to the surface of GDYO nanosheets, increasing the interaction of GDYO on ITGB2 and MRC2, respectively, and thereby enhancing the anti-leukemia effect of GDYO against DNMT3A-mutant AML cells. The gene discussed is MRC2; the disease is leukemia.